Rosiglitazone attenuates the severity of hyperlipidemic severe acute pancreatitis in rats

9Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Peroxisome proliferator-activated receptor-γ (PPAR-γ) ligand regulates adipocyte differentiation and insulin sensitivity, and exerts antihyperlipidemic and anti-inflammatory effects. However, the mechanisms by which PPAR-γ ligands affect hyperlipidemia with severe acute pancreatitis (SAP) have not been fully elucidated. The present study investigated the effects of rosiglitazone, a PPAR-γ ligand, on hyperlipidemia with SAP in a rat model. The hyperlipidemia was induced with a high-fat diet and SAP was induced by the administration of sodium taurocholate (TCA). The hyperlipidemia was shown to aggravate the severity of the sodium taurocholate-induced SAP. However, rosiglitazone demonstrated significant antihyperlipidemic and anti-inflammatory effects in the rats with high-lipid diet-induced hyperlipidemia and SAP.

Cite

CITATION STYLE

APA

Niyaz, B., Zhao, K. L., Liu, L. M., Chen, C., Deng, W. H., Zuo, T., … Wang, W. X. (2013). Rosiglitazone attenuates the severity of hyperlipidemic severe acute pancreatitis in rats. Experimental and Therapeutic Medicine, 6(4), 989–994. https://doi.org/10.3892/etm.2013.1255

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free